Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors within the central anxious program, conolidine modulates alternate molecular targets. A Science Advancements study discovered that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide avail... https://hermannw792czu2.estate-blog.com/profile